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Abstract
Background:  Both insulin and thiazolidinediones (TZDs) are effective in the treatment of
hyperglycaemia and amelioration of insulin resistance in type 2 diabetes but have side effects
including weight gain and fluid retention. The use of TZDs has been further hampered by the risk
of adverse cardiovascular events including heart failure. The present study evaluated the effect of
pioglitazone or insulin glargine on cardiac function and size as well as on surrogate markers of fluid
retention such as weight, haemoglobin and natriuretic peptides.
Methods: Thirty patients with inadequate glycaemic control on metformin and sulfonylurea were
randomised to receive add-on therapy with insulin glargine or pioglitazone for 26 weeks.
Echocardiographic data and blood samples were collected from the two groups before the start of
the treatment and after 26 weeks. Left ventricular end-diastolic and left atrial end-systolic volumes
were quantified, weight measured and blood samples analyzed.
Results: After 26 weeks of treatment, the changes in HbA1c, weight and haemoglobin were similar
between the two groups. HDL increased significantly in the pioglitazone group. While there was
an increase in natriuretic peptides in the pioglitazone group (NT-proBNP 11.4 ± 19.6 to 22.8 ±
44.0, p = 0.046), the difference between the treatment groups was not significant. Left ventricular
end-diastolic volume increased by 11% and left atrial end-systolic volume by 17% in the pioglitazone
group (Both, p < 0.05, between treatment groups). There was a borderline significant increase in
ejection fraction in the pioglitazone group.
Conclusion: This randomised pilot-study showed that six-month treatment with pioglitazone
induced significant increases in natriuretic peptides and alterations of cardiac size. These changes
were not observed with insulin glargine, which also is known to induce fluid retention. Larger
randomised trials are warranted to confirm these findings.
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Introduction
The hyperglycaemia in type 2 diabetes (T2D) is associated
with enhanced risks of micro- and macrovascular compli-
cations. The continuous deterioration of metabolic con-
trol is considered independent of mode of therapy and
ascribed to deterioration of both insulin secretion and
action. Consequently, there is no widely agreed consensus
on how to intensify therapy in patients who fail on initial
treatment with metformin and/or a sulfonylurea, espe-
cially whether to add a third oral agent, e.g., thiazolidine-
dione (TZD) or insulin. Both treatment alternatives are
considered to result in weight gain and fluid retention.
While insulin therapy requires injections and can be asso-
ciated with hypoglycaemia, TZD therapy is associated
with increased risk of heart failure. In a recent meta/teleo-
analysis Singh et al. concluded that heart failure might
occur at both high and low doses, usually weeks to
months after initiating TZDs and in patients without a his-
tory of heart failure [1]. There are, to our knowledge, no
studies that have investigated whether there are any differ-
ences between these two treatment alternatives on cardiac
size and function in patients with T2D. The present study
thus evaluated whether pioglitazone or insulin glargine
added to metformin and sulfonylurea differ in their effects
on cardiac size and function as well as in haematological
signs of fluid retention and cardiac dysfunction.
Patients and methods
Thirty patients with T2D and inadequate glycaemic con-
trol were included in a 26-week randomised open-label
trial. Inadequate glycaemic control was defined as treat-
ment with metformin and sulfonylurea/meglitinide in
doses > 50% of maximum recommended doses and
HbA1c > 6.2% measured with Mono-S method (= 7%
National Glycohemoglobin Standardisation Program,
NGSP). Patients with known heart failure or clinical signs
of heart failure (New York Heart Association class II–IV)
were excluded. Also excluded from the study were patients
with significant valvular dysfunction (defined as more
than mild regurgitation or presence of valvular stenosis),
reduced ejection fraction EF (< 50%) or inappropriate
acoustic window. Patients who met the criteria for the
study were randomly assigned to receive add-on therapy
with insulin glargine or pioglitazone for 26 weeks. Insulin
was up-titrated to achieve fasting plasma glucose < 6
mmol/l. Pioglitazone was increased to 45 mg/day after 16
weeks if HbA1c > 6.2%. Weight and height were meas-
ured, and BMI was calculated at inclusion and after 26
weeks of treatment. Blood samples were collected for
measurement of haemoglobin, liver enzymes, plasma lip-
ids, and natriuretic peptides (BNP and NT-proBNP).
Blood samples were drawn after an overnight fast, and
after at least 10 minutes rest in the supine position.
Echocardiography
Standard transthoracic echocardiography examinations
were performed with Sonos 5500 (Philips, Andover, MA,
USA) at baseline and after 26 weeks of treatment. A single
observer blinded to all clinical data performed the
echocardiography measurements, which were performed
twice with the mean value used in all analysis. From 2-D
echocardiography, left ventricular end-diastolic diameter
(LVDD), posterior wall thickness (POST) and interven-
tricularseptum thickness (IVS) were measured and left
ventricular mass (LVM) was calculated from the formula
LVM = 0.8 × 1.04 × (LVDD+IVS+POST)3-LVDD3 +0.6 [2].
Left ventricular end-diastolic volume (LVD vol), left ven-
tricular end-systolic volume (LVS vol), left atrial end-
systolic volume (LA vol), and EF were quantified by
biplane method of discs [2]. Percent change from baseline
measurements were calculated.
Assays
Plasma glucose was measured with a HemoCue glucose
analyser (Hemocue, Ängelholm, Sweden). HbA1c was
analyzed using the Variant II chromatographic method
from Bio-Rad (ref. 4–5.3%) measured by Swedish Mono-
S (high performance ion-exchange liquid chromatogra-
phy). BNP was measured with an immunoassay system
from Beckman (Biosite, Ca, USA) with a CV of 3.5% and
NT-proBNP using an immunometric method (Hitachi
Modular-E, Roche) with a CV of 4.4%.
Statistical methods
Data are presented as means ± SD where appropriate.
Non-parametric tests were used to test differences in
changes of measured variables within and between treat-
ment groups. A two-side significance level of < 0.05 was
considered statistically significant. Statistical analyses
were carried out using SPSS version 15 and Microsoft
office Excel 2003.
Results
All 30 patients completed the study. There were no signif-
icant differences in patients' anthropometrical characteris-
tics at baseline or at the end of the study (Table 1). After
26 weeks of treatment, the reduction in HbA1c was simi-
lar in groups as was weight gain and reduction in haemo-
globin levels. Pioglitazone, but not insulin glargine
resulted in an increase in HDL concentrations (1.10 ±
0.25 to 1.3 ± 0.31, p < 0.01 vs. 1.1 ± 0.37 to 1.1 ± 0.36, p
= ns, p between groups = 0.013).
Baseline BNP and NT-proBNP correlated with change dur-
ing intervention in all subjects (r = 0.79, p < 0.01). There
was a doubling of BNP and NT-proBNP concentrations in
the pioglitazone group (6.9 ± 5.2 to 14.1 ± 16.7, p = 0.10Cardiovascular Diabetology 2009, 8:15 http://www.cardiab.com/content/8/1/15
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and 11.4 ± 19.6 to 22.8 ± 44.0, p = 0.046) and no change
in the glargine group (9.7 ± 12.9 to 9.7 ± 11.6, p = 0.41
and 13.6 ± 20.0 to 10.1 ± 9.5, p = 0.97). The difference
between the treatment groups, however, was not signifi-
cant. The increase in BNP and NT-proBNP correlated
inversely with the changes in haemoglobin (r = -0.38, p =
0.041 and r = -0.47, p = 0.01) in the whole group. The
inverse correlation between increase in NT-proBNP and
the change in haemoglobin was even greater in the group
treated with pioglitazone (r = -0.59, p = 0.02) while there
was no correlation in the group treated with insulin
glargine (r = -0.016, p = 0.95). The NT-proBNP values at
baseline correlated strongly with changes from baseline
during treatment with pioglitazone (r = 0.63, p < 0.012).
None of the subjects developed clinical heart failure.
There were no significant differences in baseline echocar-
diography measurements between the groups, whereas
significant increase in LVD vol and LA vol could be
observed after six-month treatment with pioglitazone.
There were no differences in change of LVM or EF between
the two groups. Table 2 displays baseline characteristics (
± SD) and percent change in echocardiography data after
26-week treatment. There were significant correlations
between changes in BNP and NT-proBNP versus change in
LA vol in the whole group (r = 0.42 and r = 0.56, p < 0.05).
There were no significant correlations between changes in
BNP and NT-proBNP versus change in LVD vol in the
whole group (r = 0.08 and r = 0.16, both NS).
Although one patient in the pioglitazone group devel-
oped a significant mitral regurgitation during treatment,
the condition was reversible, shown by the results of an
echocardiography examination six months after discon-
tinuation of pioglitazone medication [3].
Table 1: Subjects' anthropometric and laboratory characteristics at baseline and after 26 weeks of treatment.
Pioglitazone Insulin glargine Δ pioglitazone vs. Δ insulin glargine P
Week 0 Week 26 P Week 0 Week 26 P
15 15
Men/women 11/4 9/6
Age(years) 60.8 ± 7.1 61.5 ± 8.2
Diabetes Duration (years) 11.1 ± 6 9.5 ± 7.5
BMI (kg/m2) 30.8 ± 5.5 31.9 ± 5.9 0.001 31.6 ± 6.1 32.5 ± 6.2 0.01 0.37
HbA1c (%) 8.1 ± 1.5 6.8 ± 1.2 0.001 8.3 ± 1.4 6.1 ± 0.7 0.001 0.23
Haemoglobin (g/l) 137.5 ± 11.4 127 ± 12.0 0.001 137.1 ± 10.2 132 ± 12.0 0.02 0.13
Cholesterol (mmol/l) 4.4 ± 0.9 4.2 ± 0.7 0.17 4.3 ± 1.0 4.1 ± 1.0 0.32 0.65
HDL (mmol/l) 1.1 ± 0.2 1.3 ± 0.3 0.01 1.1 ± 0.4 1.1 ± 0.4 0.49 0.01
LDL (mmol/l) 2.4 ± 0.9 2.3 ± 0.5 0.64 2.3 ± 0.7 2.4 ± 0.7 0.46 0.48
TG (mmol/l) 1.8 ± 0.8 1.5 ± 1.0 0.002 1.9 ± 1.3 1.5 ± 1.0 0.009 0.43
ALT (μcat/l) 0.7 ± 0.7 0.4 ± 0.3 0.04 0.5 ± 0.2 0.5 ± 0.2 0.12 0.87
Systolic blood pressure 142 ± 16 134 ± 10 0.04 146 ± 17 132 ± 13 0.02 0.39
Diastolic blood pressure 84 ± 8 77 ± 7 0.02 81 ± 8 73 ± 8 0.007 0.57
BNP (pmol/l) 6.9 ± 5.2 14.1 ± 16.7 0.10 9.7 ± 12.9 9.7 ± 11.6 0.41 0.51
NT-proBNP (ng/l) 11.4 ± 19.6 22.8 ± 44.0 0.046 13.6 ± 20.0 10.1 ± 9.5 0.97 0.23
Values are mean ± SD. There were no significant differences between subjects' characteristics at start or after 26 weeks of treatment.






LVDD (mm) 47.6 ± 4.0 48.7 ± 4.5 0.37
IVS (mm) 10.2 ± 0.9 10.4 ± 1.6 0.85
POST (mm) 9.0 ± 1.0 9.1 ± 1.4 0.95
LVM (g) 160 ± 33 173 ± 56 0.55
LVD vol (ml) 104 ± 23 101 ± 21 0.88
LVS vol (ml) 39 ± 11 36 ± 11 0.34
EF (%) 62 ± 5 65 ± 5 0.21
LA vol (ml) 55 ± 14 58 ± 19 0.56
Change LVM (%) 7 ± 14 1 ± 11 0.25
Change LVD vol (%) 11 ± 19 1 ± 5 0.02
Change LVS vol (%) 2 ± 15 2 ± 13 0.74
Change EF (%) 6 ± 10 0 ± 6 0.09
Change LA vol (%) 17 ± 17 2 ± 6 <0.01Cardiovascular Diabetology 2009, 8:15 http://www.cardiab.com/content/8/1/15
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Discussion
Both pioglitazone and insulin glargine added to treatment
with metformin and sulfonylurea/meglitinide in patients
with T2D was well tolerated and improved glycaemic con-
trol. In both groups a similar weight gain was observed. In
addition, pioglitazone therapy led to alterations in cardiac
volumes. The pioglitazone therapy resulted in a signifi-
cant increase in LVD vol and LA vol, as measured by
echocardiography as well as increase in levels of BNP and
NT-proBNP. However, the difference in changes of natriu-
retic peptides between groups was not significant, proba-
bly due to the small sample size and the high intra-
individual variation. Pioglitazone also increased HDL
cholesterol in keeping with previous studies. To our
knowledge, this is the first study in patients with T2D
demonstrating differences in the effect of insulin vs. a TZD
on cardiac function. The findings should, however, be
viewed with caution due to the modest sample size.
BNP and NT-proBNP are peptide hormones released from
the cardiac ventricles in response to myocyte stretch, and
have generated attention in recent years as potential diag-
nostic and prognostic markers for cardiac disease. Natriu-
retic peptides have been shown to correlate with cardiac
dysfunction, and NT-proBNP has been shown to be inde-
pendent risk marker for cardiovascular disease in patients
with diabetes [4,5]. For example, a reduction of 10 pg/ml
in Nt-proBNP is associated with a 1% relative reduction in
the cardiovascular endpoints in patients with type 1 dia-
betes and microalbuminuria [4]. There is consensus that
natriuretic peptides are useful in screening for cardiovas-
cular disease, especially in symptomatic patient popula-
tions [6]. Furthermore, natriuretic peptides carry powerful
prognostic information [6]. There are, however, currently
no clear algorithms on how these biomarkers should be
implemented into clinical practice in patients with T2D
when choosing add-on treatment or monitoring the effect
of the glucose-lowering agents.
There were no significant differences for echocardiogra-
phy measurements at baseline between the two groups,
whereas significant increase in LVD vol and LA vol could
be observed after 26-weeks treatment with pioglitazone.
These changes were of moderate magnitude as LVD vol
increased by 11% and LA vol by 17% in the pioglitazone
group. There where no significant differences in EF at
baseline and only a borderline significant increase in the
pioglitazone group after 26-weeks treatment. There are, to
our knowledge, no previous randomised studies that have
evaluated the effect of pioglitazone versus insulin glargine
on cardiac function and size in patients with T2D. St John
Sutton et al. evaluated the effect of rosiglitazone versus
glyburide in 203 patients with T2D [7]. In this study, a
similar increase in LVD vol could be detected in both
groups (12% and 19%, respectively), whereas no change
in EF could be detected. The borderline significant
increase in EF observed in the pioglitazone group in our
study could be due to volume overload, but these findings
should be interpreted with caution. The findings of
increased LVD vol by St John Sutton et al. are in line with
the findings of the present investigation that also found
an increase in LA vol. The latter finding is of interest since
LA vol has been found to be a potent prognosticator in a
variety of cardiac disorders as well as in the general popu-
lation [8]. Moreover, the finding that changes in BNP and
NT-proBNP correlated with change in LA vol is of interest
and, in part, support the use of BNP or NT-proBNP as
markers to monitor cardiac alterations in this patient pop-
ulation. The effect of pioglitazone was investigated in a
small T2D population by Hirayama and co-workers [9].
This investigation included 10 male T2D hypertensive
and 12 normotensive patients, from which echocardio-
graphic data was gathered at baseline. After a 6-month
treatment with pioglitazone, fractional shortening (a sim-
ple way of measuring EF) did not change. There was, how-
ever, a significant decrease in LVM in 12 normotensive
patients. The effect on LVD vol or LA vol was not investi-
gated. There are still other studies that have investigated
possible cardiac effects of TZDs in non-T2D populations.
Horio et al. investigated 30 non-diabetic patients with
essential hypertension and found no change in absolute
values of LA and LVDD after six-month treatment with
pioglitazone [10]. Our findings contradict this study,
which may be because of a completely different study
population.
One patient in the pioglitazone group developed a signif-
icant mitral regurgitation during the treatment, but this
was proved to be a reversible condition. An echocardiog-
raphy examination six months after discontinuation of
the pioglitazone medication showed regression of the
mitral regurgitation [3]. This finding is interesting, but of
anecdotal character and should be viewed with caution.
We have previously speculated about the explanation of
this finding [3]. One plausible hypothesis is that the fluid
retention caused left ventricular dilatation, which in turn
resulted in mitral annular dilatation. The mitral annular
dilatation then led to inadequate mitral leaflet coaptation.
In the last few years, two TZDs have been available on the
market, namely pioglitazone and rosiglitazone. Recent
meta-analyses point to differences in the effect of these
two drugs on cardiovascular outcomes. There is evidence
that the increased risk of developing congestive heart fail-
ure is greater with rosiglitazone [11]. The increased risk of
developing heart failure with pioglitazone has not been
associated with an increase in mortality [12,13]. Pioglita-
zone has also been shown to reduce incidence of ischemic
vascular events, which is not true for rosiglitazone.
Echocardiography is considered "gold standard" method,
in daily clinical practice, for evaluating cardiac function.Cardiovascular Diabetology 2009, 8:15 http://www.cardiab.com/content/8/1/15
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While an echocardiography examination is broadly avail-
able and relatively inexpensive in the western World
(150–250 Euros per examination in Sweden), the screen-
ing costs for larger groups of patients would be substan-
tial. There is, therefore, a need for less expensive
screening-tests. Taking our results into consideration, one
could suggest that an initial assessment of a natriuretic
peptide could be used for identifying individuals at risk of
responding negatively to pioglitazone treatment. Serial
monitoring of these peptides along with the clinical regis-
tration of weight and haemoglobin values during treat-
ment could also be helpful to identify those few
individuals, who should undergo an echocardiography
evaluation and subsequently reduce the rate of unwanted
side-effects.
Conclusion
When choosing pioglitazone as an add-on treatment in
patients with insufficiently controlled T2D, an increase in
LVD vol by 11% and LA vol by 17% could be observed.
This was parallel with an increase in natriuretic peptids.
These changes in cardiac volume and natriuretic peptid-
levels were not observed with insulin glargine. Larger ran-
domised trials are warranted to confirm these findings.
There is a need for tools to help clinicians to identify sub-
sets of patients for whom this kind of therapy is likely to
have particularly favourable/unfavourable effect, using
readily identifiable clinical and laboratory factors. Knowl-
edge is increasing in this field and hopefully the results
will enable clinicians to select the proper therapy for indi-
vidual patients in the future.
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